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Abstract 
 High temperature requirement A1 (HtrA1) belongs to an ancient protein family that is linked to 
various human disorders. The precise role of exon 1-encoded N-terminal domains and how these 
influence the biological functions of human HtrA1 remain elusive. In this study, we traced the 
evolutionary origins of these N-terminal domains to a single gene fusion event in the most recent common 
ancestor of vertebrates. We hypothesized that human HtrA1 is implicated in unfolded protein response. In 
highly secretory cells of the retinal pigmented epithelia, endoplasmic reticulum (ER) stress upregulated 
HtrA1. HtrA1 co-localized with vimentin intermediate filaments in highly arborized fashion. During ER 
stress, HtrA1 tracked along intermediate filaments, which collapsed and bundled in an aggresome at the 
microtubule organizing center. Gene silencing of HtrA1 altered the schedule and amplitude of adaptive 
signaling and concomitantly resulted in apoptosis. Restoration of wild-type HtrA1, but not its protease 
inactive mutant, was necessary and sufficient to protect from apoptosis. A variant of HtrA1 that harbored 
exon 1 substitutions displayed reduced efficacy in rescuing cells from proteotoxicity. Our results 
illuminate the integration of HtrA1 in the toolkit of mammalian cells against protein misfolding and the 
implications of defects in HtrA1 in proteostasis. 
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Introduction 
The high temperature requirement A (HtrA) family consists of highly conserved, multi-domain 
proteins that are present in all kingdoms of cellular life (Clausen et al., 2002). Their importance is 
underscored by the identification of developmental (Hara et al., 2009; Tiaden et al., 2012a) or age-
associated (Kooistra et al., 2009) human disorders linked to HtrAs, making this gene family a fertile 
ground for drug discovery. In recent years, human high temperature requirement A1 (HtrA1) has been the 
subject of drug discovery efforts in age-related macular degeneration (AMD) (Ciferri et al., 2015), owing 
to the prevalence of high-frequency HTRA1 variants in affected subjects (Dewan et al., 2006; Yang et al., 
2006). However, its precise role in AMD pathology remains controversial (Grassmann et al., 2017).  
The signature protein architecture of HtrA family, which consists of a core serine protease 
domain appended at the C-terminus by a postsynaptic density 95/Drosophila disc large tumor suppressor/ 
zonula occludens-1 (ZO-1) (PDZ) domain, performs dual peptide refolding and degradative chaperone 
(Malet et al., 2012) functions by oligomeric assembly (Krojer et al., 2008). Bacterial HtrAs detoxify 
misfolded proteins from various stressors (Lipinska et al., 1990; Johnson et al., 1991; Yamamoto et al., 
1996). Pairwise comparisons of protein sequences from human vs. prokaryotic HtrAs show remarkably 
high (<33%) amino acid sequence identity and supports a case in favor of ancestral protein functional 
conservation throughout evolution. This conclusion, however, has been elusive for human HtrAs. Part of 
the difficulty is the emergence of N-terminal domains that resemble IGF-binding protein (IGFBP)-like 
and TGFβ-binding-like Mac25 and Kazal-type inhibitor (KI) proteins in human HtrA1, HtrA3, and 
HtrA4, differentiating them from other members of the family and raising the question how these new 
domains might alter protein function. The structure for full-length human HtrA1 at ~10Å resolution 
places some ambiguity in the relationship between the N-terminal and core domains (Eigenbrot et al., 
2012), and the available crystal structures of human HtrA1 truncate the N-domains (Truebestein et al., 
2011; Eigenbrot et al., 2012).  
Current views of the human HtrA set ascribe discrete functions to the N-domains, often 
independent from the core. HtrA1, HtrA3, and HtrA4 are believed to be secreted proteases. The N-
terminal half are assigned growth factor binding functions (Oka et al., 2004; Tocharus et al., 2004; Hou et 
al., 2007; Kim et al., 2012; Jacobo et al., 2013). The core domains are implicated in remodeling of the 
extracellular matrix (Tiaden et al., 2012b). The catalytic serine protease domain, unlike that in 
prokaryotes, does not appear to rely on the PDZ domain for substrate capture (Truebestein et al., 2011; 
Eigenbrot et al., 2012). Presently, the challenge in the field is to demonstrate whether human HtrAs have 
dual protease-chaperone function in living cells, how the N-domains may influence this, and importantly, 
what consequences this may have to cell fate. 
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In an effort to fill the gaps in our understanding of this multi-domain protein family, we traced the 
domain accretion of Mac25 and KI as a single unit by an ancestral HtrA in the early vertebrate lineage. 
We combined this with biochemical analyses and focused on HtrA1 in the highly secretory cells of the 
retinal pigment epithelia (RPE). We report that HtrA1 was induced during chronic proteotoxicity as part 
of the unfolded protein response (UPR). We found that HtrA1 co-aligned with vimentin intermediate 
filaments (IFs), and during endoplasmic reticulum (ER) stress, trafficked to the aggresome at the 
microtubule organizing center (MTOC). HtrA1 knockdown during proteotoxicity was deleterious to 
adaptive UPR, and concomitantly resulted in cell death. This was rescued by gene augmentation with 
HtrA1, but not by variants that lacked serine protease or harbored deleterious substitutions within the 
Mac25 domain. Collectively, our work unravels an intracellular pro-survival role for HtrA1 in proteome 
homeostasis and illuminates design requirements for strategies that target HtrA1. 
Results 
HtrA innovations in the chordate lineage  
Multi-domain proteins constitute ~80% of the total collection of eukaryotic proteins (Buljan et 
al., 2010). Illuminating mechanisms of domain combination to produce signature architectures is 
rudimentary to our understanding of proteomes and evaluating functional consequences of disease-
associated variations in the human genome. 
The HtrA family of proteins are widespread in bacteria and eukaryotes, although largely absent 
from archaea (Koonin et al., 2008). Phylogenetic analysis suggested a mitochondrial origin for the 
eukaryotic HtrAs (Koonin and Aravind, 2002). A previous evolutionary study of Mac25-containing 
proteins in vertebrates placed the HtrA family in an unrelated clade from the IGFBPs, despite the fact that 
HtrA1, HtrA3, and HtrA4 share the same N-terminal Mac25 and KI domains (Rodgers et al., 2008). 
Aside from these existing reports, there is a gap in our understanding of when and how these N-domains 
were acquired by the HtrA family. 
An initial search for HtrA homologs showed that the core serine protease and PDZ domains are 
observed across essentially all eukaryotes. However, there were no HtrA proteins with N-terminal Mac25 
or KI domains in any species outside the vertebrates. Therefore, in order to trace the evolution of the HtrA 
domain architecture, we performed a phylogenetic analysis of HtrA proteins from a diverse set of 
chordate genomes (Figure 1). We can see that the invertebrate chordates, Ciona (tunicate) and 
Branchiostoma (cephalochordate), each have just a single HtrA protein lacking the N-terminal domains. 
Petromyzon (lamprey) is the most distant species from mammals where HtrA proteins with N-terminal 
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domains are observed. The proteins used for multiple sequence alignment are provided in Supplementary 
Dataset S1.  
Most of the vertebrate HtrA sequences cluster into four clear families, reflecting the HtrA1−4 
sequences in humans. HtrA1, HtrA3, and HtrA4 all possess the N-terminal domains, with HtrA1 and 
HtrA4 being most closely related. Interestingly, the two Petromyzon sequences with N-terminal domains 
are more closely related to each other, but do not cluster with other vertebrate HtrA proteins. Thus, we 
can infer the likely evolutionary origin of these families. First, there was a gene duplication of an 
ancestral HtrA gene. One of those copies is the ancestor of the HtrA2 family, while the other underwent a 
gene fusion event to acquire the N-terminal Mac25 and KI domains. This domain acquisition had 
occurred by the time of the most recent common ancestor of the vertebrates. Following this, there were 
two more gene duplication events, first with HtrA3 diverging, and then divergence between HtrA1 and 
HtrA4. Both of these duplications must have occurred by the time of our most recent common ancestor 
with the cartilaginous fish, since members of all four families are present in Callorhinchus (elephant 
shark). 
In the invertebrate chordate species Ciona intestinalis, where HtrA has not acquired the N-
domains, there are two other proteins (ENSCINP00000012789 and ENSCINP00000016757) that contain 
N-terminal Mac25 and KI domains, followed by a C-terminal immunoglobulin domain, suggesting that 
they are homologs of the human Kazald1, IGFBP7 (Mac25) and IGFBPL1 proteins (Rodgers et al., 
2008). This also suggests that the Mac25 and KI domains were acquired together via a single evolutionary 
gene fusion event from one of the ancestral IGFBP-like proteins. 
Figure 1 also shows a few peculiarities in terms of domains absent from some sequences. For 
example, all three Petromyzon sequences and the Callorhinchus HtrA2 lack C-terminal PDZ domains. 
Furthermore, one of the Petromyzon sequences lacks an N-terminal Mac25 domain, but does have a KI 
domain, while a few of the HtrA1, HtrA3, and HtrA4 sequences from other species lack one or both N-
terminal domains. It is difficult to say whether these represent genuine evolutionary changes in domain 
architecture, or whether they are due to genome annotation errors. The Petromyzon genome in particular 
is incredibly difficult to analyze, due to its high GC content, large amount of repetitive elements, and lack 
of genome sequences for any closely related species (Smith et al., 2013). Notably, the exon encoding the 
N-terminal domains has exceptionally high GC content. Thus, genome annotation errors involving these 
domains would not be surprising. 
Evolution of proteins by domain acquisition can substantially alter protein function by proving 
new activities (Rodgers-Melnick et al., 2013) and modulating the structure of pre-existing domains 
(Marsh and Teichmann, 2014, 2015). We next aimed to test whether gains in N-domains influence 
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 6 
chaperone-protease functions in human HtrAs. The case of HtrA1 is interesting, as all AMD-associated 
HtrA1 variants identified thus far reside within the promoter region upstream of the accrued exon that 
encodes the N-domains, and within this exon itself. 
ARPE-19 cells upregulate HtrA1 during chronic protein misfolding 
We set up conditions in cells so that their requirement for chaperones is a matter of life or death. 
Using cultured RPE (ARPE-19) as a model, we mimicked conditions wherein immature, misfolded 
proteins accumulate by blocking the ER-to-Golgi translocation of nascent proteins with the N-
glycosylation inhibitor tunicamycin (Kuo and Lampen, 1974), and thereby trigger ER stress (Feige and 
Scheffler, 1987). Immunoblot analyses of total ARPE-19 lysates verified the dose- and time-dependent 
activation of ER stress with a marker, the UPR master regulator immunoglobulin heavy chain binding 
protein (BiP)/GRP78 (glucose-responsive protein, 78 kDa) (Munro and Pelham, 1986). We found that 
HtrA1 was upregulated in response to chemical induction of ER stress (Figure 2A). Increased HtrA1 
translation was also accompanied by enhanced HtrA1 transcription (Figure 2B).  
BiP is a binding partner and tonic inhibitor of UPR effectors that reside at the ER membrane: 
protein kinase RNA-like ER kinase (PERK), activating transcription factor 6 (ATF6), and inositol-
requiring enzyme (IRE). We validated whether these arms of UPR were active in ARPE-19 
(Supplementary Figure S1). qRT-PCR analyses showed that the downstream transcription factor targets 
of PERK, activating transcription factor 4 (ATF4) and DNA damage inducible transcript 3 (DDIT3), were 
significantly enhanced after 1 h of tunicamycin exposure. ATF4 returned to baseline by 3 h, and DDIT3 
expression was sustained up to 24 h. Tribbles homolog 3 (TRIB3), which encodes a transcription factor 
that antagonizes CCAT/enhancer-binding protein homologous protein (CHOP; gene product of DDIT3), 
was upregulated at 3 h and sustained through 24 h chemical ER stress induction. ATF6 and IRE targets 
were upregulated as of 3 h. 
We next asked whether the ER stress-induced HtrA1 upregulation depended on the gene 
regulation network governed by BiP-dependent mediators. We found that after 6 h of chemically induced 
ER stress, HtrA1 transcription was abolished by 4μ8C, a small molecule blocker of IRE1α’s ribonuclease 
subunit (Cross et al., 2012). A Ser/Thr kinase inhibitor of PERK, GSK2606414 (Axten et al., 2012), only 
partially blocked HtrA1 transcription (Figure 2C). Neither of these inhibitors significantly affected the 
transcription of HtrA1, spliced Xbox-binding protein 1 (sXBP-1), or ATF4 in the absence of chemically 
induced ER stress. Immunoblot analyses of ARPE-19 lysates validated that suppression of HtrA1 
transcription by inhibiting IRE1α or PERK correlated with diminished HtrA1 protein. These observations 
support the conclusion that HtrA1 is upregulated during UPR in a manner that depended on IRE1α and 
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PERK (Figure 2D).  
Previously, cultured RPE chronically exposed to cigarette smoke extract had an 
overrepresentation of UPR genes and persistently active IRE1α, PERK, and ATF6. Some of these features 
were found in RPE from early AMD human subjects (Cano et al., 2014). Given these antecedents and the 
enrichment of HtrA1 risk variants in a subset of AMD subjects (Supplementary Table S1), we were thus 
curious whether in vitro surrogates (Suner et al., 2004; Supanji et al., 2013) for these stressors induce 
HtrA1 expression in RPE. We found that overnight treatment (18 h) of ARPE-19 with H2O2 or nicotine 
upregulated HtrA1, albeit only weakly increased BiP and GRP94β (glucose-regulated protein, 94 kDa) 
(Figure 2E, top box). Nevertheless, the enhanced expression of HtrA1 upon prolonged exposure to H2O2 
or nicotine resulted in upregulation of IRE1α and suppression of PERK (Figure 2E, middle box).  
Adaptive UPR results in tightly regulated ER traffic (Wei et al., 2011). HtrA1 harbors a putative 
signal peptide but lacks glycosylation (Yin et al., 2013), and we were curious whether its export from 
secretory epithelia like RPE was affected during stress response. We collected 24-h conditioned media 
and the corresponding total cell lysates from RPE and probed for exported HtrA1 by immunoblot (Figure 
2E, bottom box). During stress, the exit from cells was not suppressed, and HtrA1 export was enhanced 
relative to vehicle. Notably, the steady-state levels of HtrA1 retained in cells were at least 5 to 8-fold 
higher than that exported. This ratio of intracellular vs. exported HtrA1 was not robustly different from 
that previously observed in patient-derived lymphocytes or after heterologous expression in HEK293T 
(Jacobo et al., 2013).  
We next inquired about the relative contribution of the exported vs. intracellular pools of HtrA1 
to ER stress response in RPE. We estimated the amount of exported HtrA1 by immunoblot after resolving 
RPE conditioned media side by side with known quantities of HtrA1 standards, and administered a single 
bolus of excess anti-HtrA1 neutralizing antibodies as previously characterized (Jacobo et al., 2013). 
During ER stress, sequestration of exported HtrA1 with anti-HtrA1 antibodies that target either the N-
domains, the core domains, or just the PDZ domain did not appear to trigger ER-associated death (Figure 
2F). We reasoned that the amount of secreted HtrA1, although higher than baseline, nonetheless 
constituted a small fraction of that packaged in secretory granules. We also accounted for the likelihood 
that intracellular HtrA1 may be stranded in endosomes and unable to escape to secretory granules during 
ER stress. We probed for intracellular HtrA1 by immunostaining RPE with a monoclonal antibody raised 
against human HtrA1 core domains. Instead of detecting HtrA1 in secretory granules that are typically 
docked at punctae beneath the cell membrane, we found that HtrA1 distributed in arborized fashion, 
extending out to the cytoplasm from the perinuclear region (Figure 2G). 
Gerhardt MJ, et. al. 2017 
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HtrA1 associates with vimentin IFs and traffics to aggresome during ER stress 
HtrA1 was previously detected in intracellular compartments, where it accomplished some 
proposed tasks, including association with microtubules (MT) (Chien et al., 2009) and proteolytic 
deactivation of tuberous sclerosis complex 2 (TSC2) (Campioni et al., 2010). In light of this and our 
observations on UPR signaling cascades that possibly integrate HtrA1, we hypothesized that HtrA1 
associates with components of the cytoskeleton that are involved in ER structure and function (Lee et al., 
1989) and remodeling in times of stress (Harding et al., 2003). We validated whether HtrA1 associates 
with MTs by co-staining HtrA1 with α-tubulin (Supplementary Figure S2A). In RPE cells, this co-
localization was only partial and enriched around the nucleus. This correlated with partial overlap of 
HtrA1 with Calreticulin and ER Tracker at the perinuclear region (Supplementary Figure S2B). We did 
not observe significant HtrA1 staining when we replaced the anti-HtrA1 antibody with negative control 
(Supplementary Figure S3). Interestingly, we found that in RPE, HtrA1 fully co-aligned with vimentin 
IFs (Figure 3A, B and Supplementary Figure S3A and B). 
Whereas HtrA1 appeared arborized in resting cells (Figure 2G), 6 h ER stress induction resulted 
in enrichment of HtrA1 in collapsed structures that selectively anchored at pericentriolar foci. In some 
cases, HtrA1 was exclusively bundled at this location (Supplementary Figure S3C). Vimentin IFs were 
remodeled in similar fashion (Figure 3A). Fractional overlap of HtrA1 with vimentin IFs shows that ER 
stress slightly enhanced their co-localization, likely due to upregulation of HtrA1. In contrast, ER stress 
reduced overlap of HtrA1 and α-tubulin, which possibly reflects the reduced surface area upon collapse of 
HtrA1+ structures and their enrichment at the pericentriolar foci (Figure 3C, Supplementary Figure S2C). 
These foci are consistent with the MTOC, and are enriched in nocodazole-resistant α-tubulin post-
translationally modified with acetylation at Lys40 (Figure 3D). We quantified the number of cells/field 
wherein HtrA1 immunostaining were enriched at the MTOC (Figure 3E, black bars) and appeared as 
radially arborized or collapsed bundles (Figure 3E, white bars). We found significant enrichment of 
HtrA1 in the collapsed bundles at the MTOC in response to 6 h tunicamycin treatment. 
These observations are reminiscent of aggresomes (Johnston et al., 1998), which assemble as part 
of a transient, reversible response to unfolded proteins that are typically marked for clearance by 
ubiquitination and proteasomal degradation (Ardley et al., 2003). Aggregates that cannot be degraded by 
ubiquitination inhibit the proteasome, and then transported to the MTOC and caged by vimentin IFs for 
clearance by autophagic lysosomes. When we de-stabilized MTs and IFs with nocodazole, we observed 
diminished intensity of HtrA1 in tunicamycin-treated cells. We also observed reduction, though not full 
inhibition, of HtrA1 bundling and targeting to pericentriolar foci, where it remained co-distributed in 
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arborized fashion with unusually stable Ac-α-tubulin (Figure 3F, G and Supplementary Figure S3D). 
Finally, de-stabilization of MTs correlated with reduced overlap of HtrA1 with Calreticulin (Figure 3H).  
These findings demonstrate the requirement for intact cytoskeletal IFs and MTs in the 
upregulation of HtrA1. Given that Ac-α-tubulin marks MT regions that serve as sites for rudimentary ER 
functions (Friedman et al., 2010), and that HtrA1 is induced by UPR effectors during stress and thereafter 
traffics to aggresomes, we were next interested in the contribution of HtrA1 to the ER UPR.  
System-wide perturbations in ER UPR upon HtrA1 knockdown 
We examined the contribution of intracellular HtrA1 to ER stress by stably expressing HtrA1 
shRNA in ARPE-19 u lentivirus delivery. We accounted for the possibility that viral transduction itself 
can stimulate ER stress. In parallel to HtrA1 knockdown cells, we transduced parental ARPE-19 cells 
with lentivirus-encoded shRNA against the jellyfish green fluorescent protein (GFP) as non-HtrA1 
silencing control. We validated the efficacy of knockdown and found that at a constant dose of 
tunicamycin, stable expression of the HtrA1 shRNA, but not the GFP shRNA, prevented tunicamycin-
stimulated upregulation of HtrA1 protein (Figure 4A) and mRNA (Figure 4B).  
In metazoans, UPR relieves ER stress in two phases: a rapid and transient non-selective reduction 
in nascent peptide synthesis, and a more gradual, prolonged change of global gene expression (Ron and 
Walter, 2007). We were interested in the effect of HtrA1 ablation in this latter phase of UPR. We 
extracted total RNA from vehicle or tunicamycin-treated RPE cells at the 12 h timepoint for comparative 
gene expression analyses. In a representative subset of validated UPR genes, our treatment yielded robust 
response, and we observed statistically significant changes (upregulation or downregulation) in ~71% of 
analytes. Whereas HtrA1 knockdown under resting conditions was not deleterious to RPE, during 
proteotoxicity, it showed system-wide perturbation in UPR genes (Figure 4C). In ~65% of the targets, 
gene expression during ER stress after HtrA1 ablation was markedly different from control, with some 
genes changing in the opposite direction (Figure 4D).  
We evaluated signal relay of the BiP-dependent effectors by treating ARPE-19 cells with a 
constant dose of tunicamycin and collecting total cell lysates at various time points (Figure 4E). 
Immunoblot analysis showed that control RPE induced early and sustained IRE1α protein expression. 
This correlated with auto-activation and signal transduction, as indicated by the accumulation of phospho-
IRE1α and spliced XBP-1 within 3 h, consistent with previously reported early-onset IRE1 signaling in 
the adaptive phase of UPR (Calfon et al., 2002; Lin et al., 2007). In contrast, IRE1α upregulation in 
HtrA1 knockdown cells was delayed and correlated with relative latency and reduction in the levels of 
phospho-IRE1α and sXBP-1.  
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In control cells, PERK was downregulated after prolonged tunicamycin exposure. HtrA1 
silencing resulted in sustained PERK levels and activity at all timepoints, as indicated by Ser51 
phosphorylation of eukaryotic initiation factor 2α (eIF2α). Sustained phosphoSer51 eukaryotic initiation 
factor 2α (peIF2α) prolongs translational repression (Moreno et al., 2012) and implies an inability of 
HtrA1 knockdown cells to recover from ER stress. The protein expression of the pro-apoptotic 
transcription factor CHOP was induced after 1 h tunicamycin exposure; but unlike control cells, CHOP 
did not return to baseline upon HtrA1 silencing.  
Finally, in control cells, two ATF6 targets cAMP response element binding protein H (CrebH), 
which is encoded by cAMP response element binding protein 3-like 3 (CREB3L3), and serum response 
element binding factor 1 (SREBF1) were not robustly induced until after prolonged ER stress. In contrast, 
HtrA1 knockdown cells had early and sustained induction of ATF6 targets. The early onset of ATF6 
activation during proteotoxicity is consistent with our observation that its functional antagonism by the 
IRE1 pathway via competition for the effector unspliced XBP-1 is relieved upon HtrA1 silencing (Calfon 
et al., 2002; Harding et al., 2003).  
We cross-validated these protein expression studies with gene expression analyses (Figure 4C and 
D) and grouped together the transcripts that encode signaling effectors of the IRE1, PERK, and ATF6 
pathways. In HtrA1 knockdown cells, the IRE1α transcript ER-to-nucleus signaling protein 1 (ERN1) was 
not different from that in non-silencing control cells, but ERN2encoding IRE1β was markedly reduced. 
The BiP transcript heat-shock protein family A member 5 (HspA5) was enhanced with HtrA1 knockdown 
(Figure 4F). Transcripts encoding PERK (eukaryotic initiation factor 2 alpha kinase 3, EIF2AK3) or 
eIF2α (EIF2A) were not differentially expressed after HtrA1 knockdown. We detected significant changes 
to downstream targets of PERK. DDIT3 transcript was increased, and there was a downward trend in the 
transcript levels of TRIB3. Interestingly, protein phosphatase 1 subunit 15A (PPP1R15A) that encodes 
the protein GADD34 was reduced (Figure 4G). GADD34 is a binding partner of protein phosphatase 1 
(Novoa et al., 2003), which deactivates peIF2α. This supports our observation that HtrA1 knockdown 
results in prolonged eIF2α activation during chronic proteotoxicity (Figure 4E). Finally, HtrA1 silencing 
enhanced ATF6B expression, and, with chemical ER stress induction, robustly increased transcript levels 
of CREB3L3 and SREBF1 (Figure 4H). Notably, signal transduction of ATF6 is regulated by proteolytic 
activation by Site 1 and/or Site 2 proteases (S1P and/or S2P), which are encoded by MBTPS1 and 
MBTPS2 (Ron and Walter, 2007). Although we observed transcriptional and translational increase in 
CREB3L3 and SREBF1 upon HtrA1 knockdown, ER stress did not increase MBTPS1 and MBTPS2 
transcripts. 
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Our results indicate that suppression of HtrA1 after prolonged ER stress resulted in en masse 
transcriptional and translational perturbations that were deleterious to RPE, including widespread 
compensation in nascent peptide folding and secretory protein processing in the ER. Of the 31 chaperones 
in our probe set, 12 were significantly different between GFP shRNA and HtrA1 shRNA cells. For 
instance, Calreticulin and Calnexin were upregulated upon HtrA1 knockdown. The ER protein export 
channel Sec63 and peptidylprolyl isomerase A (PPIA) were reduced (Figure 5).  
Importantly, this was accompanied by dysregulation of the ubiquitin−proteasome system (Figure 
6). Of the 10 ubiquitin−proteasome-related transcripts in our microarray probe set, 8 were significantly 
different between control and HtrA1 shRNA cells. HtrA1 knockdown resulted in significant increase of 
the 26S-proteasome deubiquitinating enzyme ubiquitin-specific peptidase 14 (USP14). This was 
accompanied by downregulation of the E3 ligase ubiquitin-like with PHD and ring finger domains 1 
(UHRF1). Notably, in resting cells, USP14 tonically blocks ER-associated degradation by interaction 
with IRE1α (Nagai et al., 2009). Resting HtrA1 knockdown cells had elevated USP14, which was further 
enhanced during ER stress. This is consistent with our observation that HtrA1 knockdown suppressed 
levels and signaling of IRE1α (Figure 4). These data imply a positive feedback loop wherein IRE1α, at 
least in part, increases HtrA1 transcription (Figure 2). HtrA1, in return, is required for IRE1α to meet 
proper amplitude, timing, and activation during ER stress via at least two mechanisms involving 
competition with ATF6 for XBP-1 and tonic block by USP14.  
HtrA1 is required for RPE survival during ER stress 
We next asked whether rewiring of UPR as a result of HtrA1 ablation was a pro-survival 
adaptation to ER stress. Gene expression analyses revealed that cell viability indicators, such as KCNMB3 
and SLC17A2 that encode proteins to regulate cell membrane potential, showed differential expression 
after HtrA1 silencing (Figure 7A). In addition, overnight treatment with tunicamycin was cytotoxic to 
RPE that express HtrA1 shRNA, but not to those with non-silencing control (Figure 7B). We detected 
elevated levels of fragmented DNA in stressed HtrA1 knockdown cells (Figure 7C). These lines of 
evidence suggest that in RPE that are nonetheless able to upregulate quintessential chaperones like BiP 
and GRP94, HtrA1 ablation during ER stress results in cell death.  
We next inquired what minimum requirements within the HtrA1 protein architecture are required 
for RPE survival during ER stress. Allelic variants of HTRA1 mapped to the exon 1 are enriched in a 
subset of AMD patients (Dewan et al., 2006; Yang et al., 2006; DeAngelis et al., 2008). Of particular 
interest are those harboring Ala34(C>T) and Gly36(G>T) (Supplementary Figure S6A and B) within the 
very N-domains that were acquired by gene fusion in the vertebrate lineage. Previously, we demonstrated 
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that the protein product harboring these silent substitutions displayed altered biophysical properties that 
were due, in part, to frequent-to-rare conversion of codons (Jacobo et al., 2013). Applying similar rare vs. 
common codon analyses (McInerney, 1998) to the full-length exon 1, we matched the codon usage for 
degenerate amino acids as a function of the conserved domains (Supplementary Figure S4C). The 
residues forming ordered α-helical or β-stranded structures were spanned by common, rapidly translated 
codons, whereas islands of rare, slowly translated codons correlated with intrinsically disordered loops 
(Komar et al., 1999). In this heat map, Ala34(C>T) and Gly36(G>T) extended a rare codon cluster, and 
thus likely, at least in part, accounts for the reduction in mRNA translation speed and altered protein 
surface accessibility for the misfolding prone “double single nucleotide polymorphisms” (dSNP) HtrA1 
variant (Jacobo et al., 2013). We also observed lower levels of dSNP HtrA1 compared to WT in the 
absence of a continuous supply of newly synthesized HtrA1 to replace those post-translationally 
degraded. Thus, the silent substitutions in N-domains of HtrA1 modify post-translational stability and 
turnover.  
We tested the hypothesis that HtrA1 N-domain variants compromise adaptive UPR. We 
chemically induced ER stress with tunicamycin (1.12 μM, 18 h) in B-lymphocytes derived from 
unaffected controls and AMD affected subjects, who are homozygous for HTRA1 variants as described 
above, and evaluated gene expression of UPR indicators. B-lymphocytes from unaffected controls 
enhanced gene expression of XBP-1 and TRIB3 in response to ER stress. In contrast, this was not 
observed in affected samples harboring homozygous HtrA1 N-domain substitutions (Supplementary 
Figure S6F). 
Next, we delivered lentivirus-encoded shRNA, which targets 3’ untranslated region (UTR) of 
HtrA1 transcript to ARPE-19. For gene replacement, knockdown cells were thereafter transduced with 
empty vector (EV) retrovirus or retrovirus harboring HtrA1-coding region for recombinant WT, dSNP, 
Ser328Ala, or truncated Mac25KI, but not 3’UTR. Immunoblot analyses of ARPE-19 total cell lysates 
showed successful step-wise generation of cell lines for mutational analyses (Figure 7D).  
Under treatment conditions that were toxic to HtrA1 knockdown cells, restoration of WT 
prevented ER-associated cell death. The protease inactive S328A mutant failed to rescue knockdown cells 
from apoptosis. Truncation of the N-domains did not appear to severely compromise RPE during 
proteotoxicity (Figure 7E and F). In contrast, RPE cells harboring dSNP showed diminished such HtrA1 
ability comparable with WT (Figure 7F). Furthermore, restoration of WT suppressed genomic DNA 
fragmentation in response to tunicamycin, while overexpression of  dSNP showed reduced effect (Figure 
7G). Indeed, RPE harboring dSNP had diminished tolerance for a subtoxic dose and prolonged exposure 
to tunicamycin. We conclude that although the absence of the N-domains did not appear to diminish the 
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efficacy of HtrA1 protein to rescue knockdown cells, the presence of deleterious HtrA1 substitutions 
result in a protein product with reduced ability to protect RPE from ER stress-associated cell death. 
Discussion 
We demonstrate in this study that HtrA1, a multi-domain protein that is frequently variant in a 
subset of AMD patients, performs intracellular functions in RPE. Our data show that HtrA1 plays a role 
in the homeostatic establishment of protein quality control and is essential for RPE survival under 
conditions of proteotoxicity. Deficits in HtrA1, mimicked here by suppressed availability of exported or 
intracellular pools, loss in serine protease activity, or the presence of a misfolding-prone N-terminal 
moiety, compromised tolerance to proteoxicity, in spite of retaining ability to induce quintessential 
chaperones .  
The historic link between HTRA1 genetic variants and inherited susceptibility to AMD have been 
called into question by more recent association studies with increased population sizes and refined 
statistical models (Grassmann et al., 2017). In addition, although various overexpression studies in the 
mouse eye have implicated HtrA1 in the proteolysis of Bruch’s membrane’s and enhanced choroidal 
neovessel extravasation (Vierkotten et al., 2011; Jones et al., 2011), these phenotypes are poorly penetrant 
in mice even after achieving double-digit augmentation or combination with environmental risk factors 
(Kumar et al., 2014; Nakayama et al., 2014). Taken together with our findings, a paradigm that emerges 
suggests that although HtrA1 may not be a major culprit in inherited risk to AMD, it appears to have 
rudimentary functions in stress response.   
In our gene replacement experiments, the protective function of HtrA1 against proteotoxicity is 
compromised by a conformationally altered N-terminal moiety. Previous studies highlighted the 
frequency of intrinsically disordered regions in gained domains of multi-domain proteins. It is tempting to 
speculate that our data hints at the origins of intrinsic disorder from ancestral noncoding sequences that 
eventually became exonized (Buljan et al., 2010). This raises the interesting possibility of altered 
assembly of quaternary complex, modified substrate-induced activation, subcellular localization, and 
importantly, binding partners that may have emerged upon N-domain accretion. 
We traced the evolutionary origins of N-domains in HtrA family to the acquisition of a single 
exon from one of the ancestral IGFBP-like proteins (IGFB7) in Ciona. In a previous report, when HtrA1 
far exceeds IGF-1 levels in cell-free solution, we co-immunoprecipitated IGF-1 with purified, full-length 
or affinity-tagged Mac25/KI fragments of HtrA1, and pre-incubation of IGF-1 with HtrA1 prevented 
ligand-mediated IGF1R activation in cultured endothelial cells (Jacobo et al., 2013). The affinity of 
HtrA1 for IGF-1 was several orders of magnitude above that of IGFBPs (1 pM) or IGF-1R (10 pM) 
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(Rodgers et al., 2008). We were able to reproduce TGFβ1 co-immunoprecipitation with HtrA1 as 
previously reported (Oka et al., 2004). These data point to the conclusion that although N-domains of 
human HtrA1 retained the structure of homologous conserved domains, they have lost stereotypical 
functions of those discrete units. Interestingly, vasculopathy-associated mutations in HtrA1 that abolish 
its protease activity (Hara et al., 2009) and ability to oligomerize (Nozaki et al., 2016), but harbor the 
anti-TGFβ-like KI domain, are unable to antagonize TGFβ signaling. The in vivo relevance of human 
HtrAs serving as a growth factor sink is unclear, partly because there is a circulating suicide inhibitor in 
the blood (Hu et al., 1998), and only HtrA1 mutants that lack serine protease activity (Hara et al., 2009) or 
ability to oligomerize were able to evade covalent complex formation with α1-antitrypsin (Nozaki et al., 
2016).  
Sequestration of exported HtrA1 with neutralizing antibodies did not compromise RPE survival 
during ER stress. Indeed, most of the HtrA1 we detected in ARPE-19 was intracellular, though ER stress 
did not prevent exit traffic from cells. These findings raise the question how cells export HtrA1. HtrA1 
has been detected in its full-length precursor form with the signal peptide still intact (Didangelos et al., 
2010) in exosomes derived from RPE (Wang et al., 2009), heart (Prunotto et al., 2013), and osteoblasts 
(Xiao et al., 2007). These antecedents, and observations that HtrA1 lacks glycosylation (Yin et al., 2013), 
prompted us to visualize subcellular localization of HtrA1. We found that HtrA1 fully co-aligned with 
vimentin IFs. Co-localization with MTs was only partial, and specifically, detectable where there is Ac-α-
tubulin. Thus, apart from the regulation of cell cycle (Schmidt et al., 2016) and migration (Chien et al., 
2009), HtrA1 association with these cytoskeletal filaments is critical to rudimentary proteome 
maintenance.  
In summary, our findings unravel a possible role for HtrA1-mediated RPE damage in AMD. 
Deleterious substitutions in HtrA1 lower the ER stress threshold of RPE, and collapse in proteome 
homeostasis may be an event that contributes to RPE degeneration in the subset of patients with genetic 
lesions in HtrA1. The subcellular localization of HtrA1, mode of extracellular export, and repertoire of 
binding partners illuminate design requirements for interventional strategies that aim to target HtrA1 and 
HtrA1-mediated signaling pathways for therapy. 
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Materials and methods 
Phylogenetic analyses  
 HtrA protein sequences were compiled from a diverse set of species. Most sequences came from 
Ensembl (Yates et al., 2016), except those from Branchiostoma floridae (Putnam et al., 2008) and 
Callorhinchus milli (Venkatesh et al., 2014). One of the sequences from Petromyzon marinus 
(ENSPMAP00000002693) had an N-terminal KI domain, but not Mac25 domain. However, upon 
inspection of the Ensembl Genscan ab initio predicted proteins, a further N-terminal extension of the 
sequence was identified that included the Mac25 domain, and the sequence was extended to include this. 
Another Petromyzon marinus sequence (ENSPMAP00000002696) did not have Mac25 or KI domains, 
but inspection of the ab initio sequences revealed an N-terminal extension containing a KI but not Mac25 
domain. All sequences are provided in Supplementary Dataset S1. Domain assignments were performed 
for all sequences using SUPERFAMILY (Oates et al., 2015). Domains labeled as Mac25, KI, serine 
protease, and PDZ were predicted to belong to the “growth factor receptor domain”, “Kazal-type serine 
protease inhibitor”, “trypsin-like serine protease”, and “PDZ domain-like” families, respectively. 
A multiple sequence alignment was generated using ProbCons (Do et al., 2005). This was used 
with MrBayes (Ronquist et al., 2012) to generate a phylogenetic tree, using a mixed amino acid model 
and a 4-category gamma distribution with invariant sites. Using Markov Chain Monte Carlo, two chains 
were run for 1.2×106 generations with sampling every 100 generations. The average standard deviation 
of split frequencies was 0.005. The phylogenetic tree was visualized and midpoint rooted using FigTree. 
Domain schematics were generated with PROSITE MyDomains (Hulo et al., 2008). 
 
Tunicamycin-induced proteotoxicity in ARPE-19 
 Reagents used in this study were from Sigma-Aldrich unless otherwise indicated. ARPE-19 
(ATCC) were seeded in 12-well plates (250×103 cells/well) using DMEM/F12 with 10% FBS. Cells 
were serum-starved for 24 h prior to the experiment, and then treated with tunicamycin or vehicle 
(DMSO) at various time points. Cells were washed with PBS and lysates were harvested for real-time 
qRT-PCR or immunoblot for markers of UPR. In Figure 2C and D, we pre-incubated ARPE-19 cells for 1 
h with the IRE1α inhibitor 4μ8C (Tocris Bioscience; 7-Hydroxy-4-methyl-2-oxo-2H-1-benzopyran-8-
carboxaldehyde). Alternatively, we also treated cells with a kinase inhibitor to PERK, GSK2606414 
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(Tocris Bioscience, 1-[5-(4-Amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-2,3-dihydro-1H-indol-1-
yl]-2-[3-(trifluoromethyl)phenyl]ethanone). For side by side comparisons of the efficacy of oxidant 
stressors in inducing HtrA1 expression, ARPE-19 cells were cultured and serum-starved as described 
above, and thereafter exposed to H2O2 (0.5 mM) or nicotine (2.0 μM) for 24 h. Total cell lysates were 
collected for immunoblot. For measurements of cell viability (Figure 7), cells were treated with 
tunicamycin and monitored for signs of cell death under brightfield microscopy, and viable cells were 
counted with hemocytometer. 
 
Real-time qRT-PCR 
 For all real-time qRT-PCR analyses, ARPE-19 cells were seeded in 6-well plates (500×
103 cells/well). Cells were washed 2× with PBS, and then lysed in RNA-bee (AMS Bio) for total RNA 
collection. For one-step qRT-PCR in Figure 1B, 100 ng total RNA was used as template in a 20 μl 
reaction using a Power SYBR Green RNA-to-CT 1-step kit (Applied Biosystems). For all other qRT-PCR 
experiments, 1.0 μg total RNA was used in a 20 μl reverse transcription reaction using a High-Capacity 
cDNA Reverse Transcription Kit. This RT reaction was diluted 10-fold, and 2 μl was used in a 20 μl real 
time PCR with Power SYBR Green PCR master mix (Applied Biosystems). The probes used in these 
studies are listed in Supplementary Table S2. In addition, we collected total RNA after 12 h of 
tunicamycin exposure for the RT2 ProfilerTM PCR Array Human Unfolded Protein Response (Qiagen). 
Data QC and analyses were performed as described by Qiagen. 
 
Western blot 
 Total cell lysates (50 μg/well) were resolved in 4%−16% tris-glycine gels (Bio-Rad) and 
transferred to PVDF membranes. For comparisons of relative secreted vs. intracellular HtrA1, 24 h 
conditioned media were collected and clarified of cell debris by centrifugation for 1 min at 13000 g. An 
aliquot of conditioned media (50 μl of 1000 μl in total) or total cell lysates (50 μg of ~1000 μg in total) 
were resolved in protein gels side by side with known quantities of purified full-length human HtrA1 
standard (B-Bridge International). Membranes were incubated overnight with primary and HRP-
conjugated secondary antibodies (Supplementary Table S3) and developed with ECL. 
 
Immunofluorescence staining 
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 ARPE-19 cells were cultured to confluence on laminin-coated glass coverslips. Cells were serum-
starved for 24 h, rinsed, and treated for 6 h with vehicle (DMSO) or tunicamycin (5.62 μM) in serum-free 
DMEM/F12. In Figure 3, after 4 h of vehicle or tunicamycin treatment, nocodazole (5 μM) was added to 
the culture medium and cells were exposed to the treatments for an additional 2 h. At the end of the assay, 
cells were loaded with 1.0 μM ER tracker DPX blue dye (Molecular Probes, ThermoFisher) and 
incubated in the dark for 15 min at 370C. Cells were rinsed with PBS and immediately fixed in  4% PFA 
for 5 min at RT. Cells were permeabilized and blocked for non-specific immunoreactivity with buffer 
containing 0.1% triton X-100, 3% BSA, and normal serum (5% final, Sigma-Aldrich). Cells were stained 
overnight with HtrA1 antibodies and co-stained with cytoskeletal (α-tubulin or vimentin) or ER markers 
(Calreticulin). For negative control, an equal molar dose of non-immune rabbit IgG (sc-2027, Santa Cruz 
Biotechnology) was used in place of the anti-HtrA1 antibody. Cells were rinsed and incubated with Alexa 
Fluor 488-conjugated (for mouse anti-HtrA1) or Alexa Fluor 594-conjugated (for counterstained protein 
markers) AffiniPure goat anti-rabbit F(ab)2 (Jackson Immunoresearch) for 1 h at RT. Coverslips were 
mounted on UltraTM Frost glass slides (Denville Scientific) with Prolong Gold antifade reagent (Cell 
Signaling Technology). 
 
Laser-scanning confocal imaging 
 All imaging experiments are representative of four independent experiments with duplicate 
coverslips. For each coverslip, randomly selected fields were imaged by sequential scanning of each 
channel using a Leica upright DM 6000S. RGB images at 630× magnification were acquired from 
optical slices of <3.0 μm thickness at a resolution of 600 ppi using Confocal Leica Application Suite AF 
software (v. 1.3.1). Images were imported as 16-bit grayscale images into Fiji ImageJ. In every field, 
~10−15 cells were highlighted as ROI and analyzed using Coloc2 and Colocalization Threshold. The 
pixel intensity correlation of HtrA1 and counterstain were expressed as Pearson’s correlation coefficient 
and co-localized pixel maps. The differences in proportion and co-occurrence in objects from different 
channels were accounted for Manders correlation coefficient with Costes thresholding and plotted 
fractional channel overlap as percentage. 
 
Lentivirus-mediated HtrA1 knockdown 
Short hairpin RNAs that target human HtrA1 exons were selected from The RNAi Consortium of Broad 
Institute and synthesized at the Core-RNA Interference Screening Facility of Dana-Farber Cancer 
Institute. We selected the pLKO.1-encoded shRNA with the target sequence 5’-
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CGCCATCATCAACTATGGAAA-3’. Viral particles containing the shRNAs were produced by triple 
transfection of HEK293T cells (1.0×106) with 1.0 μg total cDNA using TransIT293 (Mirus Bio). The 
target plasmid was mixed with pCMV-ΔR8.91 packaging and pMD2.G envelope plasmids to produce 
VSV-G pseudotyped lentiviral particles that were used to infect P20-21 ARPE-19. Stable cell lines 
harboring this exon-targeted HtrA1 shRNA were used for Figure 4 and Supplementary Figures S3, S4. 
For gene replacement experiments, we generated and screened three hairpin sequences that target 
different portions of the 3’UTR of the human HtrA1 mRNA, and selected the forward oligonucleotide 5’-
CCGGAGAATCCTTCTTGATAGTTTGCTCGAGCAAACTATCAAGAAGGATTCTTTTTTG-3’ and 
the reverse oligonucleotide 5’-
AATTCAAAAAAGAATCCTTCTTGATAGTTTGCTCGAGCAAACTATCAAGAAGGATTCT-3’. 
These were annealed, ligated to pLKO.1, and validated by Sanger Sequencing (MGH DNA Sequencing 
Core). Lentiviral particles were generated for infecting ARPE-19 cells. Stable cell lines harboring this 
3’UTR-targeted HtrA1 shRNA plus recombinant cDNA were used in Figure 7. All experiments described 
here used cells that were selected in puromycin (2.0 μg/ml) and thereafter validated for HtrA1 knockdown 
using western blot and qPCR. 
 
Ethics statement 
 This study was reviewed and approved by the Institutional Review Boards at the Massachusetts 
Eye and Ear Infirmary and the University of Utah, and conforms to the tenets of the Declaration of 
Helsinki. Written informed consent was obtained from all participants. 
 
Subjects and phenotypes 
 Details of recruitment diagnostic criteria and subject classification were described previously 
(Silveira et al., 2010). Genotype and statistical analyses of human subject data were described in detail 
previously (Jacobo et al., 2013). Data in Supplementary Figure S4A, B and Table S1 differ from this prior 
work in the inclusion of early AMD and geographic atrophy (GA) patients. 
 
Post-translational degradation of HtrA1 
We transfected 1.0 ×106 HEK293T cells with 1.0 μg plasmid encoding EV (pCINeo, Promega), WT, or 
dSNP. At 24 h post-transfection, cells were washed and serum-starved in DMEM/F12 for 24 h. At the 
peak of protein expression (48 h), transfected cells were treated with cycloheximide (CHX, 100 μM) to 
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inhibit nascent protein synthesis. After 8 h, total cell lysates were collected and analyzed by immunoblot. 
The amount of HtrA1 in the CHX-treated cells reflects the net turnover at the peak of transfection minus 
that from post-translational degradation, in the absence of new HtrA1 synthesis.  
 
Retrovirus-mediated expression of recombinant HtrA1 
 Recombinant human HtrA1 cDNA templates were PCR-amplified using the forward primer 5’-
CATGCGGCCGCCACCATGCAGATCCCGCGCGCCGCT-3’ and the reverse primer 5’-
AATGTCGACCTATGGGTCAATTTCTTCGGGAATCAC-3’ from pCINeo templates encoding wild-
type (WT), “double SNP” (dSNP), S328A, and truncated HtrA1 that lacks Mac25 and KI domains 
(dMacKI) as previously described (Jacobo et al., 2013), and then cloned into the NotI and SalI sites of the 
retrovirus vector pLNCX2. All cDNA plasmids were validated by Sanger Sequencing. The target 
plasmids were packaged into VSV-G pseudotyped retrovirus, and then used for transducing puromycin-
resistant ARPE-19 cells that stably express HtrA1 mRNA 3’UTR-specific shRNA (described above). 
Retrovirus-transduced ARPE-19 were selected using G418 (1.2 mg/ml), and neomycin-resistant ARPE-
19 were validated for recombinant HtrA1 overexpression using immunoblot. 
 
Cytosolic nucleosome ELISA 
 Briefly, 96-well clear-bottomed plates were coated with anti-histone antibody for 1 h at RT. 
ARPE-19 total cell lysates (5 μg/well) were diluted in the incubation buffer to a final volume of 100 
μl/well. Samples in duplicate were equilibrated on the coated plates for 90 min at RT. To measure 
apoptosis-associated DNA fragmentation, we followed the manufacturer’s protocol for Cell Death ELISA 
(Roche Life Sciences). 
 
Data analysis and statistics 
 Data analyses were performed with Prism 4.0 (GraphPad). Where appropriate, two-tailed 
student’s t-test was used for paired comparisons. One-way ANOVA followed by Tukey’s post-hoc test 
was used for comparison of more than two groups; Dunnett’s post-hoc test was used for comparison of 
multiple groups against vehicle or time 0 baseline. Comparisons wherein *P<0.05 at α≥0.05 were 
considered statistically significant. 
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Figure legends 
Figure 1 Molecular evolution of the chordate HtrA set.  
Figure 2 RPE cells upregulate HtrA1 during ER UPR. (A) Dose- and time-dependent upregulation of 
HtrA1 protein after tunicamycin-induced proteotoxicity. Induction of ER stress was validated by probing 
for BiP (positive control). Ras GTPase-activating protein (RasGAP) served as loading control. 
Immunoblots are representative of n>3 experiments. (B) HtrA1 transcript was upregulated during ER 
stress. Relative gene expression was calculated with 0 h as reference. ***P<0.001, n = 3. (C) Blockers of 
IRE1α ribonuclease (4μ8C, 100 nM) or PERK kinase (GSK2606414, 10 nM) suppressed HtrA1 mRNA 
upregulation during 6 h ER stress induction with tunicamycin (11.2 μM). sXBP-1 (IRE1α target) or ATF4 
(PERK target) was  used as positive control. *P<0.05, n = 4. (D) Blockers of UPR prevented HtrA1 
protein upregulation during ER stress. Immunoblot validation of HtrA1 gene expression analyses in C. 
*P<0.05, n = 3.  (E) Cells upregulated HtrA1 after overnight treatment with oxidizing stressor H2O2 (0.5 
mM) or nicotine (2 μM). Immunoblots are representative of n>3 experiments. (F) Sequestration of 
exported HtrA1 with neutralizing antibodies did not compromise ARPE-19 cell viability. ARPE-19 cells 
were stimulated with tunicamycin (5.62 μM). After 6 h, anti-HtrA1 antibodies against the N-domain, the 
core domain, or the C-terminal domain were added to the conditioned media. The final concentrations 
were 208−533× in molar excess to the amount of HtrA1 typically exported by ARPE-19 within 24 h ER 
stress. After additional 18 h of incubation (in total 24 h treatment), brightfield images were collected to 
monitor overt signs of toxicity. Images are representative of three random fields per coverslip (n = 3). 
Scale bar, 100 μm. (G) Intracellular localization of HtrA1 in ARPE-19 cells. Cells were immunostained 
with monoclonal anti-HtrA1 antibody, and counterstained with ZO-1 or DAPI. scale bar, 10 μm.  
Figure 3 HtrA1 associates with vimentin IFs and traffics to the MTOC during chronic proteotoxicity. (A) 
HtrA1 (green channel, panels ii, v) co-localized with vimentin IFs (red channel, panels i, iv) in vehicle-
treated and ER-stressed ARPE-19 cells. In co-localized pixel maps (panels iii, vi), white areas show 
HtrA1 and vimentin pixel co-distribution (highlighted by yellow arrowheads). Scale bar, 10 μm. (B) 
Pearson correlation coefficients showed greatest co-occurrence of HtrA1 with vimentin IFs. *P<0.05. (C) 
The percentage of co-localization channels was plotted after validating Mander’s correlation coefficient 
with Costes thresholding. *P<0.05. (D) Immunostaining of Ac-lys40-α-tubulin (panels i, iv) and HtrA1 
(panels ii, v) showed bundling and enrichment at the MTOC during ER stress. Scale bar, 10 μm. (E) 
HtrA1 was enriched at the MTOC after 6 h ER stress. We surveyed cells/field wherein HtrA1+ structures 
were selectively enriched at the MTOC (*P = 0.0246, paired t-test) or collapsed bundles (*P = 0.0257, 
paired t-test) and plotted the percentage of cells under resting or stressed conditions. Numbers above the 
bars indicate total number of surveyed fields (10−15 ROIs/field), encompassing n=3 experiments. (F and 
G) De-stabilization of MTs and vimentin IFs attenuated HtrA1 trafficking to MTOC (F). Co-localized 
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pixel maps showed diminished overlap of HtrA1 with Ac-MTs and IFs after nocodazole treatment (G). 
Yellow arrowheads point to channel co-localization examples. Images are representative of fields 
surveyed as described in A−D. Scale bar, 10 μm. (H) De-stabilization of MTs uncoupled HtrA1 and ER. 
The percentage of channel overlap of HtrA1 (green) with calreticulin (red) in vehicle-treated or stressed 
cells with nocodazole. *P<0.05. 
Figure 4 System-wide perturbation of ER UPR after HtrA1 ablation favors pro-apoptotic over adaptive 
signaling. (A and B) Immunoblot and real-time qRT-PCR validation of lentivirus-mediated delivery of 
human HtrA1 shRNA in RPE. (C and D) HtrA1 deficit during chronic proteotoxicity resulted in system-
wide changes in UPR transcripts. Average relative gene expression of analytes after 12 h tunicamycin 
(5.62 μM) treatment were shown as heat map (C). (D) Control vs. HtrA1-deficient cells displayed 
significantly different UPR pathway activation scores. ***P<0.001, n = 3. (E) HtrA1 deficit during 
proteotoxicity disrupted signal relay of IRE1, PERK, and ATF6. Total cell lysates were collected as 
described in A and B (n = 3 independent experiments). (F−H) Gene expression analysis of IRE1 (F), 
PERK (G), and ATF6 (H) pathway effectors. Total RNA was collected for gene expression analysis as in 
C. Relative mRNA levels were normalized to values from vehicle-treated GFP shRNA controls. *P<0.05, 
n = 3. 
Figure 5 HtrA1 knockdown results in dysregulation of the chaperone network in RPE. (A and B) Gene 
expression analyses of control and HtrA1-deficient cells after 12 h treatment with vehicle or tunicamycin 
(5.62 μM) showed significant differences in chaperones involved in nascent peptide folding (A) or 
secreted protein processing (B). (C−E) Randomly selected analytes were validated for qRT-PCR and 
immunoblot consistency.  
Figure 6 HtrA1 knockdown leads to dysregulation of the ubiquitin−proteasome system in RPE. (A) Gene 
expression analyses of control and HtrA1-deficient cells after 12 h treatment with vehicle or tunicamycin 
(5.62 μM) showed significant differences in genes involved in the ubiquitin-proteasome system. (B−D) 
Three analytes were randomly picked to validate qRT-PCR and  immunoblot consistency.  
Figure 7 HtrA1 is required for survival during proteotoxic stress. (A) HtrA1 silencing during 
proteotoxicity downregulated transcripts for indicators of cell membrane potential, including the β3 
subunit of the MaxiK K+ channel (KCNMB3), Na+:PO4-3 symporter SLC17A2, and the growth factor 
modulator INHBE. **P<0.01, n = 3. (B) HtrA1 silencing during chronic proteotoxicity led to ER-
associated death. Representative phase contrast images of control vs. HtrA1-deficient ARPE-19 cells after 
24 h treatment with vehicle or tunicamycin (5.62 μM). Scale bar, 100 μm. (C) HtrA1 silencing during 
chronic proteotoxicity increased ER stress-associated genomic DNA fragmentation and cytosolic 
nucleosome accumulation after 24 h tunicamycin (5.62 μM) treatment. ****P<0.0001, n = 4. (D) 
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Retrovirus-mediated gene transfer of recombinant human HtrA1 into HtrA1 knockdown ARPE-19. 
Immunoblot showed successful gene transfer of WT, dSNP, the protease inactive point mutant S328A, 
and the truncation mutant ΔMacKI into resting ARPE-19 cells expressing HtrA1 3’UTR shRNA. (E) 
Restoration of WT HtrA1 into HtrA1 knockdown RPE rescued cells from proteotoxic cell death. Serum-
starved cells were treated with tunicamycin (5.62 μM) for 24 h, and brightfield images were collected to 
monitor cells for signs of overt cytotoxicity. Scale bar, 100 μm. (F) Restoration of WT HtrA1 into HtrA1 
knockdown RPE suppressed stress-induced genomic DNA fragmentation. (G) Substitutions in HtrA1 
Mac25 domain diminished  ER stress threshold of RPE to subtoxic dose of tunicamycin. 
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